Michael Linsey, MD
Nephrology · Pasadena, CANPI 1841215217
Payments from drug & device makers
Across 17 payments — averaging $40.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$208
- Vifor Pharma, Inc.$200
- Otsuka America Pharmaceutical, Inc.$122
- Novartis$65
- Calliditas Therapeutics US Inc.$60
- OPKO Pharmaceuticals, LLC$18
- plus $12 from 1 others
What the payments were for
- Speaking & faculty fees$20029%
- Food & beverage$42362%
- Education$619%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 7 | $208 |
| Vifor Pharma, Inc. | 1 | $200 |
| Otsuka America Pharmaceutical, Inc. | 3 | $122 |
| Novartis | 3 | $65 |
| Calliditas Therapeutics US Inc. | 1 | $60 |
| OPKO Pharmaceuticals, LLC | 1 | $18 |
| Fresenius USA Marketing, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$200
How this compares
$684 in reported general payments places this provider in the 35th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 137 | $136,232 |
| LokelmaSodium Zirconium Cyclosilicate | 25 | $23,958 |
| TradjentaLinagliptin | 21 | $10,961 |
| Sevelamer Carbonate | 25 | $9,855 |
| JardianceEmpagliflozin | 12 | $8,380 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 27 | $7,157 |
| Calcium Acetate | 34 | $4,461 |
| Tacrolimus | 19 | $3,836 |
| Febuxostat | 18 | $2,181 |
| Cinacalcet Hcl | 16 | $1,884 |
| Losartan Potassium | 111 | $1,209 |
| Metolazone | 15 | $1,144 |
| Carvedilol | 104 | $1,131 |
| Torsemide | 47 | $1,028 |
| Mycophenolate Mofetil | 15 | $945 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Pasadena
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
- Glenn ChertowStanford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.